Simon N Waddingon

Learn More
The development of robust nonviral vectors could facilitate clinical gene therapy applications and may overcome some of the immune complications of viral vectors. Nevertheless, most nonviral gene deliver approaches typically yield only transient and/or low gene expression. To address these caveats, we have explored piggyBac transposons to correct hemophilia(More)
SHORT TITLE PiggyBac hyperactive transposons for hemophilia A and B 3 ABSTRACT The development of robust non-viral vectors could facilitate clinical gene therapy applications and may overcome some of the immune complications of viral vectors. Nevertheless, most non-viral gene deliver approaches typically yield only transient and/or low gene expression. To(More)
  • 1